AbbVie (ABBV) announced on Monday that it has entered into a partnership with Jacobio Pharmaceuticals, to jointly develop and commercialize SHP2 inhibitors, which target a key node in cancer and immune cells.Financial terms of the partnership were not disclosed. Under the terms of the agreement, AbbVie will be granted an exclusive license to the SHP2 portfolio. Meanwhile, Jacobio will continue to conduct early global clinical trials of JAB-3068 and JAB-3312 inhibitors, while AbbVie will cover the R&D expenses.SHP2 is a protein mediator of cellular signaling. Many tumors have genetic mutations, driving abnormal cancer cell growth which relies on SHP2 activity. SHP2 also plays a key role to control cytokine production and immune cell response.Therefore, inhibition of SHP2 is believed to have dual effects by potentially reducing cancer cell growth and modulating immune responses to generate anti-tumor activities. Jacobio's early clinical stage SHP2 assets, JAB-3068 and JAB-3312, are oral small molecules designed to specifically inhibit SHP2 activity."Identifying promising...
There is a laser-precision technique that tells us whether the precious metals market is going to move higher or lower, and it could take form of a …...
Shares in Immutep (IMMP) are surging 10% in Monday’s pre-market trading after the company announced first interim data from its ongoing INSIGHT-004 Phase I clinical trial at the 2020 American Society of Clinical Oncology’s (ASCO) Annual Meeting.The Frankfurt-based study is a phase I trial evaluating the combination of Immutep’s lead product candidate, eftilagimod alpha (“IMP321” or “efti”) with avelumab, a human anti-PD-L1 antibody, in 12 patients with solid cancers. Avelumab is co-developed and co-commercialized by Merck KGaA (MRK), Darmstadt, Germany and Pfizer Inc (PFE).Patients in cohort 1 receive 6mg doses of efti every two weeks with the standard dose of avelumab (800mg every two weeks), while patients in cohort 2 receive a higher dose of efti, 30mg, with avelumab.According to the presentation, 33% of patients (4 out of 12) showed a partial response (PR) to the combination therapy. In cohort 2, 3 patients out of 6 have not yet had their response assessed...
Stock futures were mixed Monday morning, steadying against a backdrop of protracted protests in some of the nation’s largest cities, many of which had already been struggling to reopen amid the coronavirus outbreak....
Nio Inc. - ADR (NYSE: NIO) Chief Executive Officer William Li on Sunday told Bloomberg that the Chinese electric vehicles maker sees rival Tesla Inc. (NASDAQ: TSLA) more as an ally than a competitor.What Happened "We do compete against each other, but in general we are allies," Li said, as reported by Bloomberg, pointing out that the two companies are working to grab the market from gasoline-based automakers rather than each other."In fact, our sales kept growing since Tesla started production in Shanghai," he added.Li's comments come days after Nio reported mixed earnings for the first quarter this year, as the COVID-19 pandemic took toll.It posted a loss per ADS of 22 cents, narrower than the analyst consensus of 26 cents, and highlighted enhanced cost control measures taken in the quarter.What's Next Li told Bloomberg that the long-term growth outlook for the electric vehicles market in China remains the same despite...
(Bloomberg) -- U.S. stock-index futures pared losses and European shares climbed as investors weighed signs of economic recovery with the possibility of renewed trade trictions with China. Contracts on the S&P 500 and the Nasdaq 100 gauges were little changed after falling earlier in the day, when Bloomberg reported that state-owned traders Cofco and Sinograin were ordered to suspend purchases of some American farm goods including soybeans. After a weekend when violent protests spread across major U.S. cities, markets started the week with a measure of calm. Travel companies and banks led gains in the Stoxx Europe 600 Index, and copper advanced in London. Germany and Switzerland were closed for a holiday.Economic reports also sounded a faint note of optimism. The Caixin manufacturing PMI rose to 50.7 in May, indicating an expansion. Euro-area data on Monday also signaled factories have started down their long road to recovery.“Signs of improvement in growth...